Skip to main content

Aggregator

Democrats Rake in $833 Million Through ActBlue Ahead of Midterms

1 day 23 hours ago
The Democratic fundraising organization ActBlue raised $833 million for the party’s candidates and causes in the third quarter, a record amount that will help narrow the financial advantage the GOP enjoys with big donors in what is projected to be the most expensive election in US history.
Bill Allison

HeartBeam Consensus Price Target Increased by 10.53% to $3.57

1 day 23 hours ago
The average one-year price target for HeartBeam (NASDAQCM:BEAT) has been revised to $3.57 / share. This is an increase of 10.53% from the prior estimate of $3.23 dated September 11, 2026. These figures represent aggregate analyst targets compiled as of September 29, 2026, and do
Fintel

HeartBeam Consensus Price Target Increased by 10.53% to $3.57

1 day 23 hours ago
The average one-year price target for HeartBeam (NASDAQCM:BEAT) has been revised to $3.57 / share. This is an increase of 10.53% from the prior estimate of $3.23 dated September 11, 2026. These figures represent aggregate analyst targets compiled as of September 29, 2026, and do
Fintel

Piper Sandler Upgrades Alerus Financial to Overweight from Neutral

1 day 23 hours ago
On October 2, 2026, Piper Sandler upgraded their outlook for Alerus Financial (NASDAQCM:ALRS) (DB:5QD) from Neutral to Overweight. This rating action follows a prior action by the same firm on July 31, 2026, when Piper Sandler maintained its Neutral rating on the stock.Alerus Fin
Fintel

AEON Biopharma Consensus Price Target Raised by 16.39% to $1.81

1 day 23 hours ago
The average one-year price target for AEON Biopharma (NYSEAM:AEON) has been revised to $1.81 / share, up 16.39% from the prior estimate of $1.56 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation o
Fintel

AEON Biopharma Consensus Price Target Raised by 16.39% to $1.81

1 day 23 hours ago
The average one-year price target for AEON Biopharma (NYSEAM:AEON) has been revised to $1.81 / share, up 16.39% from the prior estimate of $1.56 dated September 11, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not constitute a recommendation o
Fintel